ABOUT TRANSPORT

About Transport

Transport Pharmaceuticals, Inc., is a privately held, clinical-stage specialty pharmaceutical company revolutionizing the treatment of dermal diseases by bringing together cutting-edge medical electronics, drug formulation and materials science to develop novel drug/device combination products. This unique combination of technologies can enhance the delivery of topically applied drugs and the utility of potent systemically delivered drugs whose uses are limited by bioavailability, toxicity or side effect concerns.

The core competencies (engineering, chemistry, biology and drug development) of Transport's experienced team converge to enable the unique combination of cutting edge microprocessor-controlled drug delivery device technology with proprietary formulations of known drugs, pre-loaded into patient friendly, unit-dose drug applicators. The resulting products can improve the effectiveness of existing drugs and change the way dermatological conditions are treated.

Drug/Device Convergence

The Cores of Drug/Device Convergence
Transport's team is comprised of experienced engineers, chemists, biologists, clinical development and regulatory experts. The convergence of all of these disciplines in a highly focused company enables the design and development of Transport's unique drug/device combination products.

Lead Product

The company’s lead product, SoloVir™ Electrokinetic Transdermal System (ETS) link to SoloVir™ ETS fact sheet for the treatment of herpes labialis, is based on the combination of iontophoresis, a technology employing a low-voltage current to enhance the penetration of drugs through the skin, and a proprietary acyclovir formulation that has been optimized for iontophoretic delivery.

In addition, the company has a strong pipeline of pre-clinical and clinical-stage products for onychomycosis, acne, actinic keratosis, psoriasis, keloids and warts, where efficacy of existing topical drugs can be dramatically improved.

Recent Events

• Completed Phase 2 human clinical trial of SoloVir™ ETS, a drug/device combination product for herpes labialis.
• Completed Phase 1 human clinical trials for SoloVir™ ETS, a drug/device combination product for herpes labialis.
• Demonstrated delivery of unprecedented amounts of acyclovir into the skin with SoloVir™ ETS, in human clinical trials.
• Raised total of $29.6 million in Series D venture financing to fund next-generation formulation of SoloVir™ ETS, a drug/device combination product for herpes labialis and new clinical candidates for dermatological indications.
• Published proof-of-concept Phase 2 clinical results with first-generation iontophoretic device and 5 percent acyclovir cream in the August 15, 2006 issue of Journal of Clinical Dermatology.
• Filed patent applications on the SoloVir™ ETS, including the iontophoretic device, high solubility acyclovir formulation and unit-dose drug cartridge.

Download Corporate Fact Sheet